EGF and COVID-19: Furthermore, the surviving and non-surviving severe COVID-19 patients showed significantly increased levels of circulating EGF, VEGFA, SVEGFR2, SVEGFR3 and sEGFR compared to the healthy controls (surviving patients vs. controls: p < 0.0001, p < 0.0001, p < 0.0001, p = 0.006 and 0.014, respectively; non-surviving vs. controls: p = 0.003, p < 0.0001, p = 0.002, p = 0.002 and p = 0.013, respectively).